Medline's recent initial public offering, hailed as 2025's largest, has sparked a key debate in private equity. Carlyle's Robert Schmidt argued the listing provides Medline with a powerful cost of capital currency. This public market access is now seen as a strategic tool for funding future acquisitions and creative deal-making.

The successful offering suggests investor appetite for scaled, high-quality assets is returning after a prolonged drought. For private equity firms sitting on large portfolio companies, Medline's exit validates the IPO window as a viable path to liquidity. It provides a benchmark for valuing similar businesses and may encourage other sponsors to pursue public listings.

Expect more large-scale PE-backed companies to test public markets if conditions hold. The Medline deal could catalyze a pipeline of offerings from firms seeking to return capital to investors. Market participants will watch closely for follow-on activity and whether this opening remains durable for other scaled assets awaiting an exit.